Abstract:Flow chart of patient enrollment and table of EGFR exon 19 deletion (ex19del) variants, with Kaplan–Meier curve for progression free survival (PFS) and overall survival (OS) of first‐line tyrosine kinase inhibitor (TKI) treatment and incidence of secondary T790M mutation, in EGFR ex19del mutations subgroups. (A, B) Comparison of PFS and OS between the classic and nonclassic EGFR ex19del group; (C) PFS in the EGFR ex19del subgroup with deletion starting at E746 accompanying insertion mutation (E746/ins+), comparing with the patients with other ex19del variants; (D, E), comparison of PFS and OS of first‐line therapy with first‐, second‐, and third‐generation (gen.) tyrosine kinase inhibitor (TKI) in patients with classic EGFR ex19del group; (F, G) comparison of PFS and OS of first‐line therapy with first‐, second‐, and third‐generation (gen.) TKI in patients with nonclassic EGFR ex19del group; (H) incidence of secondary T790M after resistant to first or second generation TKIs, in each subgroup of EGFR ex19del, and comparison between the classic and nonclassic EGFR ex19del groups, between EGFR ex19del subgroups starting at E746 and at other site (ex19del/E746+ vs. ex19del/other site), between EGFR ex19del subgroups with and without insertion mutations (EGFR ex19del/ins+ vs. EGFR ex19del/ins−), and between EGFR ex19del subgroups with deletion length of 15 nucleotides or of other deletion length (ex19del/15+ vs. ex19del/other length). Background Clinical significance of various subtypes of epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) remains unclear. Methods We analyzed EGFR ex19del subtypes in NSCLC patients receiving first‐line tyrosine kinase inhibitor (TKI) therapy at our center (January 2018–June 2022) and correlated them with median progression‐free survival (mPFS) and median overall survival (mOS). Results We identified 17 different EGFR ex19del variants in 101 patients. Between the classic (E746_A750del, 64.4%) and nonclassic groups (the rest variants), no significant difference was observed in mPFS (13.5 vs. 19.3 months, p = 0.18) or mOS (44.1 vs. 77.0 months, p = 0.06). mPFS showed no significant difference between ex19del subgroups classified based on the presence of insertion (ex19delins), starting position or length of deletion. However, patients with ex19delins starting at E746 showed longer mPFS than the others (29.7 vs. 12.5 months, p = 0.04), and patients with ex19del of 15 nucleotides had shorter mOS than the others (44.1 vs. 77.0 months, p = 0.03). In multivariate analysis, ex19delins independently predicted a better PFS (HR = 0.311, p = 0.03); however, 15 nucleotide deletion was no longer associated with OS (HR = 0.181, p = 0.11). Secondary T790M mutation incidence was significantly higher in the ex19del subgroup starting at E746 than the others (64.7% vs. 30.8%, p = 0.04). Conclusions Our study revealed potential differences in TKI efficacy, resistance mechanism, and prognosis of various EGFR ex19del subtypes in NSCLC, underscoring the need for precise selection of first‐line therapy.

Molecular characteristics of EGFR exon 19 deletion subtypes in NSCLC patients.

Different Stories for Different EGFR Exon 19 Deletion Variants

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients.

The Impact of EGFR Exon 19 Deletion Subtypes on Clinical Outcomes in Non-Small Cell Lung Cancer

A Multicenter-Retrospective Study of Non-Small-cell Lung Carcinoma Harboring Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations: Different Subtypes of EGFR Exon 19 Deletion-Insertions Exhibit the Clinical Characteristics and Prognosis of Non-Small Cell Lung Carcinoma

Molecular Characteristics of EGFR Exon20 Mutations in NSCLC Patients.

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study

Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors.

Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs

The Difference of Clinical Characteristics Between Patients with Exon 19 Deletion and Those with L858R Mutation in Nonsmall Cell Lung Cancer.

[Mutations in Exon 19 of EGFR Gene in Non-Small Cell Lung Cancer from Chinese Patients].

Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.

Abstract 2906: Intratumor heterogeneity of non-small-cell lung cancer with EGFR mutations

The Expression of EGFR Exon 19 Deletion and Its Clinical Significance in the Squamous Cell Lung Cancer,lung Adenocarcinoma

Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors

Egfr Exon 19 Insertions: A New Family of Sensitizing Egfr Mutations in Lung Adenocarcinoma

EGFR with TKI-sensitive Mutations in Exon 19 is Highly Expressed and Frequently Detected in Chinese Patients with Lung Squamous Carcinoma.

EGFR exon 20 insertion mutations in non-small cell lung cancer